SACHI trial
-
HUTCHMED Announces Publication of Phase III SACHI Trial Results in The Lancet
The Lancet publication of HUTCHMED’s SACHI trial results demonstrates savolitinib plus osimertinib’s efficacy in advanced NSCLC with acquired MET-amplified resistance to EGFR-TKIs. This combination offers a significant treatment advancement, with prior regulatory approval in China. The findings support precision medicine, expand oncology pipelines, and highlight the value of strategic partnerships. Further global trials are underway to broaden market access.
